PTAB Denies Request to Cross-Examine Experts Because Declarations Were Prepared for Other Proceedings and Were Not “Critical” Evidence

Nov 7, 2018

Reading Time : 1 min

Under 37 C.F.R. § 42.51(b)(1)(ii), “[c]ross examination of affidavit testimony prepared for the proceeding is authorized within such time period as the Board may set” (emphasis added). Nestlé argued that, even though the declarations were not prepared for the IPR proceeding, Steuben should produce the witnesses for deposition because the “declarations were recently created, and . . . Patent Owner has not asserted that the Declarants are unavailable,” citing IBG LLC et al. v. Trading Technologies Internationale, Inc., CBM2015-00179, Paper 39 (PTAB Apr. 15, 2016). The Board rejected that argument and distinguished the IBG case. In IBG, the Board ordered the petitioner to produce a witness from a prior litigation because the witness’s testimony “was the sole evidence that a reference was prior art.”  Here, Nestlé “d[id] not allege that Patent Owner’s evidence rises to such a critical level.”

The Board did not reach Nestlé’s alternative request to exclude the declarations because Nestlé had not filed a motion to exclude.

Practice Tip:  When seeking to cross-examine witnesses based on declarations from prior or parallel proceedings, parties should include in their requests an explanation of why the declaration is “critical” evidence in the IPR. Parties should also consider objecting to the declarations by filing a motion to exclude that includes a reasoned explanation justifying exclusion.

Nestlé Healthcare Nutrition, Inc. v. Steuben Food, Inc., IPR2015-00249, Paper 107 (PTAB Oct. 29, 2018).

Share This Insight

Previous Entries

IP Newsflash

June 5, 2026

The Supreme Court unanimously held that for a complaint of induced infringement, a patent owner must allege that the accused infringer took affirmative, not passive, steps to encourage direct infringement. Thus, where a generic drug has a skinny label, to induce infringement of the carved-out patented use of the drug, the generic company must have taken steps that were designed to cause others to perform the patented use, not just steps that could cause such conduct.

...

Read More

IP Newsflash

May 07, 2026

The Northern District of Illinois granted a summary judgment motion of no invalidity based on indefiniteness because the qualitative terms like “sufficiently slow” and “desired period of time” were definite when viewed in light of the surrounding claim language and specification.

...

Read More

IP Newsflash

April 9, 2026

In the April 1, 2026 edition of the Official Gazette, the U.S. Patent and Trademark Office announced a new procedural framework that permits patent owners to submit a limited, early response to a request for ex parte reexamination.

...

Read More

IP Newsflash

March 12, 2026

The Northern District of Illinois recently dismissed a complaint without prejudice for failing to plausibly allege patent infringement. The court found that the allegations of direct infringement were insufficiently pled where the images of the accused product included in the complaint did not appear to show a particular necessary element of the claims.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.